Pancreatic Cancer Blood Test — Early Detection Before Symptoms
Pancreatic cancer has no recommended screening for the general population, and 85% of cases are diagnosed at advanced stages when treatment is most difficult. EPISEEK® is a multi-cancer early detection (MCED) blood test that screens for signals of pancreatic cancer — alongside more than 60 other cancer types — by analyzing DNA methylation patterns in a single blood draw. Results are returned in 7–10 days from a CAP-accredited, CLIA-certified laboratory.
Why pancreatic cancer is so difficult to detect
Pancreatic cancer is often called a “silent” disease because early-stage tumors rarely cause obvious symptoms. By the time pain, weight loss, or jaundice appear, the cancer has typically progressed beyond curative surgical options. The pancreas sits deep behind the stomach, making it difficult to image incidentally, and there are no widely-recommended screening tests like there are for breast, colon, or cervical cancers.
The result: the 5-year survival rate for pancreatic cancer is 13%, the lowest of any major cancer type. But when caught at stage 1, before regional spread, that survival rate rises to 44%. Early detection is the single most important factor in outcomes.
How EPISEEK® detects pancreatic cancer signals
EPISEEK® analyzes DNA methylation patterns in circulating cell-free DNA (cfDNA) — small fragments of genetic material released into the bloodstream by cells throughout the body, including tumor cells. When cancer cells release their cfDNA, that material carries epigenetic markers that distinguish it from healthy cells.
Specifically, EPISEEK® looks for hypermethylated DNA loci — regions of DNA that show consistent abnormal methylation across multiple cancer types, including pancreatic adenocarcinoma. This methylation-based approach is supported by peer-reviewed validation studies and reviewed in independent literature.
What EPISEEK® can detect
- Pancreatic adenocarcinoma (the most common type, ~95% of cases)
- Other pancreatic malignancies that share epigenomic signatures
What EPISEEK® does not do
- Replace imaging (CT, MRI, endoscopic ultrasound) when cancer is suspected
- Replace genetic testing for familial cancer syndromes
- Provide a definitive diagnosis — positive signals require follow-up workup
Who should consider EPISEEK® for pancreatic cancer screening
EPISEEK® is appropriate for adults aged 21+ who want proactive screening that includes pancreatic cancer signals. The case for screening is strongest if you have:
- Family history of pancreatic cancer (especially first-degree relatives)
- Genetic predisposition — BRCA1/2, Lynch syndrome (MLH1, MSH2), Peutz-Jeghers (STK11), FAMMM (CDKN2A), hereditary pancreatitis (PRSS1)
- New-onset type 2 diabetes after age 50 (associated with elevated pancreatic cancer risk)
- Chronic pancreatitis of more than 5 years’ duration
- Heavy long-term tobacco use
- Body mass index over 30
- Age 45 or older
Talk to your healthcare provider about whether EPISEEK® screening is right for your situation. Our self-service ordering flow includes provider review.